Wave Life Sciences: Increased Probability of Success Drives Buy Rating Amid Platform Advancements
Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on Wave Life Sciences (WVE – Research Report) and increased the price target ...
Positive Outlook for Wave Life Sciences Driven by Promising RNA Editing Data and Strategic Opportunities
Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed’s rating is ...
The Australian Names The Country’s Top 100 Innovators In Glossy Pull-Out
The Australian has published its fourth annual edition of The List – Top 100 Innovators 2024: The Next Wave. Identifying the ...
The Pharma Letter12h
Takeda terminates deal with Wave
RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of ...
Zacks.com on MSN18h
Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?
Wave Life Sciences (WVE) shares rallied 74.1% in the last trading session to close at $14.90. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
Fintel on MSN18h
Raymond James Upgrades Wave Life Sciences (WVE)
Fintel reports that on October 16, 2024, Raymond James upgraded their outlook for Wave Life Sciences (NasdaqGM:WVE) from ...
Petri Dish: Takeda splits from Wave; Lilly backs Alzheimer’s biotech
This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...